FORM 6 - K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 of
The Securities Exchange Act of 1934
For the month of September 2000
Commission File Number 0-29350
VASOGEN INC.
(Translation of Registrant's name into English)
2155 Dunwin Drive, Suite 10, Mississauga, Ontario, L5L 4M1
(Address of principal executive offices)
(Indicate by check mark whether the registrant files or will file annual reports
under cover Form 20 - F or Form 40 - F.)
Form 20 - F [X] Form 40 - F [_]
(Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of
1934.)
Yes [_] No [X]
This Form 6-K consists of:
A press release issued by Vasogen Inc. on September 26, 2000, entitled: "Vasogen
Added to the TSE 300 Composite Index".
SIGNATURE
---------
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
VASOGEN INC.
By /s/ Christopher Waddick
---------------------------------------
(Name: Christopher Waddick)
(Title: Vice-President, Finance & CFO)
Date: September 26, 2000
<PAGE>
Vasogen Inc.
INVESTOR CONTACT
2155 Dunwin Drive
Mississauga, ON, Canada L5L 4M1 Glenn Neumann
tel: (905) 569-2265 fax: (905) 569-9231 Investor Relations
www.vasogen.com tel: (905) 569-9065
e-mail: [email protected]
--------------------------------------------------------------------------------
FOR IMMEDIATE RELEASE
Vasogen Added to the TSE 300 Composite Index
Toronto, Ontario (September 26, 2000) -- Vasogen Inc. (TSE:VAS; AMEX:MEW) today
announced that it has been selected to be included on the TSE 300 Composite
Index under the Biotechnology/Pharmaceuticals section of the Consumer Products
sub-index. This inclusion becomes effective after the close of trading on the
Toronto Stock Exchange (TSE) today.
The TSE 300 Composite Index, introduced in 1977, is a broad market indicator
that represents 300 of the largest publicly-traded companies in Canada. The TSE
regularly reviews the Indices and follows strict criteria for inclusion and
maintenance policies to ensure that the Indices continually provide key
information for investors.
"We are very pleased to be included in the select group of companies which
comprise the TSE 300 Index," commented David Elsley, President and CEO of
Vasogen. "With five indications in clinical trials, a solid financial position
and a strong research pipeline to support future growth, Vasogen remains
committed to enhancing shareholder value through the commercial development of
its proprietary immune modulation therapy for the treatment of a number of
autoimmune and inflammatory diseases."
Over the next three quarters, Vasogen expects to report results from five
ongoing clinical trials targeting the treatment and prevention of psoriasis,
peripheral vascular disease, congestive heart failure, ischemia/reperfusion
injury, and graft-versus-host disease.
Vasogen is focused on developing immune modulation therapies to advance the
treatment of cardiovascular, autoimmune and related inflammatory diseases.
These therapies are designed to target fundamental disease-causing events,
providing safe, effective treatment.
Statements contained in this press release, including those pertaining to
scientific and clinical research, commercialization plans, strategic alliances,
and intellectual property protection, other than statements of historical fact,
are forward-looking statements subject to a number of uncertainties that could
cause actual results to differ materially from statements made.
